CRISPR Therapeutics Quarterly Income Statement
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRISPR Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, CRISPR Therapeutics generated $10.2 million in revenue, up 1041.4% from the same quarter a year earlier. CRISPR Therapeutics reported a net loss of $91.2 million, compared with a loss of $208.5 million a year earlier. Operating margin was -1151.8%.
Diluted earnings per share came in at -$0.94.
Summary generated from market data by MetaCap's automated system. Methodology
CRISPR Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.18M | 1.46M | 864.00K | 889.00K | 892.00K | 865.00K | 35.69M | 602.00K | 517.00K | 504.00K | 201.21M | 0 |
| Revenue growth (YoY) | +1041.37% | +68.55% | -97.58% | +47.67% | +72.53% | +71.63% | -82.26% | — | -99.26% | -99.50% | +3353333.33% | -100.00% |
| Operating Expenses | 127.45M | 131.71M | 155.63M | 132.95M | 230.22M | 149.29M | 100.28M | 110.73M | 151.78M | 141.09M | 131.62M | 132.41M |
| Research & Development | 67.15M | 68.57M | 83.53M | 58.90M | 69.89M | 72.48M | 71.74M | 82.16M | 80.17M | 76.17M | 95.14M | 90.70M |
| Operating Income | -117.27M | -130.25M | -154.76M | -132.06M | -229.32M | -148.42M | -64.59M | -110.13M | -151.26M | -140.59M | 69.58M | -132.41M |
| Interest Expense | 3.32M | 553.00K | — | — | 0 | 0 | — | — | — | — | — | — |
| Other Income (Expense) | 27.07M | 8.16M | 24.77M | 26.24M | 22.07M | 13.54M | 27.98M | 25.06M | 26.14M | 24.72M | 20.00M | 20.67M |
| Pretax Income | -90.19M | -122.09M | -130.00M | -105.82M | -207.26M | -134.89M | -36.61M | -85.07M | -125.12M | -115.87M | 89.58M | -111.74M |
| Income Tax | 960.00K | 839.00K | 614.00K | 619.00K | 1.29M | 1.11M | 700.00K | 876.00K | 1.29M | 724.00K | 233.00K | 412.00K |
| Net Income | -91.15M | -122.93M | -130.61M | -106.44M | -208.55M | -136.00M | -37.31M | -85.94M | -126.41M | -116.59M | 89.35M | -112.15M |
| Net Income growth (YoY) | — | — | — | — | — | — | -141.76% | — | — | — | — | — |
| EPS (Basic) | -0.94 | -1.28 | -1.32 | -1.17 | -2.40 | -1.58 | -0.41 | -1.01 | -1.49 | -1.43 | 1.12 | -1.41 |
| EPS (Diluted) | -0.94 | -1.28 | -1.32 | -1.17 | -2.40 | -1.58 | -0.41 | -1.01 | -1.49 | -1.43 | 1.12 | -1.41 |
| Shares Outstanding (Basic) | 96.51M | 96.05M | — | 91.31M | 87.07M | 85.94M | — | 85.23M | 84.92M | 81.79M | — | 79.41M |
| Shares Outstanding (Diluted) | 96.51M | 96.05M | — | 91.31M | 87.07M | 85.94M | — | 85.23M | 84.92M | 81.79M | — | 79.41M |
| EBITDA | -112.99M | -125.93M | -149.10M | -127.63M | -224.68M | -143.69M | -59.75M | -105.39M | -146.41M | -135.75M | 74.48M | -127.49M |
| Operating Margin | -1151.84% | -8933.33% | -17912.50% | -14854.78% | -25708.97% | -17158.84% | -180.96% | -18294.02% | -29257.25% | -27894.25% | 34.58% | — |
| Net Margin | -895.33% | -8431.48% | -15117.25% | -11973.12% | -23379.93% | -15722.08% | -104.54% | -14276.08% | -24450.29% | -23133.13% | 44.41% | — |
This table shows 12 quarterly periods of CRISPR Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow CRSP's reporting calendar. What is a income statement?